Pain, Postoperative
Conditions
Keywords
Adverse Drug Reaction, Morphine, Oxycodone, Abdominal hysterectomy
Brief summary
The objective of this study is compare adverse reactions associated with oxycodone and morphine for the treatment of postoperative pain after abdominal hysterectomy
Detailed description
A randomized single-blind study, was performed to compare the adverse reactions associated with oxycodone and morphine in patients undergoing abdominal hysterectomy. process: 1. A clinical history of patients candidates to participate in the study will be developed. 2. If you meet the selection criteria will be held the invitation to participate in the study, reading the letter under information Patients who agree to participate in the study will be managet during the surgical procedure: 15 mg mixed blockade with bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg intravenously during surgery metamizol 3) After the surgical procedure (immediate postoperative) • the patient to group A or B (randomization) is assigned, masking infusions and allocation will be conducted by an outside person who will test an additional record the names of the patients and the drug administered. A bolus of oxycodone or morphine 10% calculated dose for intravenous infusion 0.075mg intravenous palonosetron prophylaxis of emesis Detection and assessment of severity of adverse drug reactions will be conducted by an interview that will be at 0,1,2,6,12 and 24 hours after the onset of analgesia. Instrument designed for the detection of RAM will be used and classify its severity according to common terminology criteria for adverse events (CTCAE). Futhermore, measuring systemic blood pressure, heart rate, oxygen saturation will be performed through the use of Nihon Kohden monitor (model BSN-2301K). Pain assessment will be made by the numerical scale (NRS). The researcher responsible for the detection and assessment of adverse reactions to opioids and others determinations, remain mowed.
Interventions
DRUGMorphine
Interventions pre-specified to be administered to participants: Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery Intravenous infusion: 200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours
DRUGOxycodone
Interventions pre-specified to be administered to participants: Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery Intravenous infusion: 150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours.
Sponsors
Hospital Civil de Guadalajara
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients scheduled for abdominal hysterectomy * Signing for informed consent
Exclusion criteria
* Patients used with MAO inhibitor drugs (\<14 days before surgery) * History of substance abuse * Hypersensitivity to opioids and others drugs of multimodal analgesia (metamizol and lidocaine) * Pretreatment of any opioid (\<7/2 lives of the drug in question) * Chronic pain of any etiology (\> 6 months) * Diagnosis of bowel obstruction * Renal or hepatic insufficiency * Asthma, chronic obstructive pulmonary disease (COPD), and/ or hypothyroidism. * Patients requiring general anesthesia for surgical complications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse drug reactions (questionnaire) | 24 hours | Nausea, vomiting, respiratory depression, dizziness, headache, sedation, pruritus and anaphylaxis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative pain (Numeric Pain Rating Scale) | 24 hours | — |
| systemic blood pressure (mmHg) (physiological parameter) | 24 hours | Monitor Nihon Kohden BSM-2301K |
| Heart rate (physiological parameter) | 24 hours | Monitor Nihon Kohden BSM-2301K |
| Oxygen saturation (physiological parameter) | 24 hours | Monitor Nihon Kohden BSM-2301K |
Contacts
Primary ContactVIRGINIA A SANCHEZ, MD
Outcome results
None listed